Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

STT 01

Next Previous
Drug Profile

STT 01

Alternative Names: Anti-CD274 antibody - STCube Pharmaceuticals; Anti-PD-L1 antibody - STCube Pharmaceuticals; Anti-programmed cell death-1 ligand-1 antibody - STCube Pharmaceuticals; STT-001; STT-01

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator STCube Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Developer STCube Pharmaceuticals
  • Class Antibodies; Antineoplastics; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Apr 2025 No recent reports of development identified for preclinical development in Solid-tumours in South Korea (Parenteral)
  • 07 Apr 2023 Preclinical development for Solid tumours is ongoing in South Korea (STCube Pharmaceuticals pipeline, April 2023)
  • 31 Jul 2018 STT 01 is available for licensing as of 31 Jul 2018 (STCube Pharmaceuticals website, July 2018)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top